Bristol Myers Squibb weighs dividend reset, shares trade near recent lows

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 11:55.

Bristol Myers Squibb (US0897961004) draws renewed attention on the NYSE as investors reassess the stock’s income profile and valuation after this year’s marked dividend cut and a weak share price performance, according to recent market commentary on the S&P 500 healthcare sector.Reuters sector wrap

What analysts are watching now

Analyst discussions around Bristol Myers Squibb focus on three concrete variables: the lower absolute dividend payout, the pipeline’s ability to offset key patent losses and the valuation gap to large pharma peers such as Pfizer and Merck. MarketScreener consensus overview MarketScreener data show a consensus rating in the Buy to Outperform corridor, with a majority of the roughly 20 tracked houses recommending accumulation and an average 12?month target price in the low?to?mid 60?dollar range, clearly above the current share level. This implies a double?digit percentage upside in analyst models, although the spread between the most cautious and the most optimistic targets remains wide.

Income?oriented investors are recalculating the yield: after the dividend reset earlier this year, the forward yield is materially lower than the historic average but still compares competitively with US Treasury yields and with several US pharma peers when measured against current NYSE prices, according to recent broker notes cited in the consensus overview.Financial Times healthcare dividend analysis

Consensus on earnings and patent headwinds

On the earnings side, analyst models compiled by MarketScreener project that Bristol Myers Squibb will generate adjusted earnings per share in a mid?single?digit to high?single?digit dollar range over the next two fiscal years, with a cautious growth trajectory reflecting erosion from the loss of exclusivity on legacy blockbusters.MarketScreener earnings estimates The revenue mix is shifting toward newer oncology, hematology and cardiovascular products, but several lines still face intense competition from generic and biosimilar entrants.

Research houses highlight the company’s sizeable late?stage pipeline and bolt?on deals as partial offsets to these headwinds, but they generally model only modest organic growth in the medium term, with upside tied to successful launches and label expansions. In this context, Bristol Myers Squibb is often compared with Pfizer, Merck and Johnson & Johnson in sector studies, where it screens as a value?tilted large?cap pharma with higher specific product risk but also a lower earnings multiple than the S&P 500 healthcare average, per recent US broker commentary.Bloomberg big pharma valuation piece

How Bristol Myers Squibb makes its money

Bristol Myers Squibb generates the bulk of its revenue from branded prescription medicines in oncology, hematology, immunology and cardiovascular disease, including well?known therapies such as the immuno?oncology drug Opdivo and the oral anticoagulant Eliquis, which it co?markets with Pfizer.BMS quarterly earnings materials The company’s pipeline spans small molecules, biologics and cell therapies, with a focus on indications where it believes high unmet medical need supports premium pricing and long patent lives.

Where the stock trades today

The Bristol Myers Squibb shares (US0897961004) most recently traded on the NYSE at around 54.70 US dollars on 2026-06-22, according to aggregated price data, after an intraday range between roughly 54.00 and 54.73 dollars in moderate trading volume.Yahoo Finance BMY quote

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other kind of financial advice. All data are based on sources considered reliable but without any guarantee; prices and assessments may change at any time.